Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Rapamycin for the Treatment of SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For SLE Subjects:~* SLE patients who exhibit ongoing disease activity by SLEDAI greater or equal to 4.~* SLE patients whose disease activity is controlled by administration of corticosteroids, most commonly, at least 10 mg/day of prednisone.~* 18 years of age or older.~* Updated vaccinations prior to study entry.~* Use of effective contraception for male patients before, during and up to 12 weeks after sirolimus therapy.~For Healthy Control Subjects:~* 18 years of age or older~* Must be matched with one of the SLE patients enrolled in the study by age, gender and ethnic origin~* Must not have any acute or chronic illness.~Exclusion Criteria:~For SLE Subjects:~* Patients who are pregnant.~* Patients with allergy or intolerance to sirolimus.~* Patients with life-threatening manifestations of SLE.~* Patients with proteinuria exceeding 500 mg/24 h or urine protein/creatine ratio \>0.5.~* Patients with total cholesterol \> 300 mg/dl or triglyceride \> 400 mg.dl will be excluded.~* Patients with acute infection requiring antibiotics.~* Patients on sirolimus who develop infections and require intravenous antibiotics and fail to show clinical improvement in 5 days.~* Patients concurrently undergoing B cell-depleting therapy, cyclophosphamide, cyclosporine, and tacrolimus.~* Patients who have received investigational biologic B-cell depleting products within one year of study initiation.~* Patients with a history of chronic viral infections (e.g., HIV, hepatitis B, hepatitis C) or with a history of a malignancy (except non-melanoma skin cancer).~* Due to interference with sirolimus metabolism, subjects will not be allowed to receive concomitant rifampin, ketoconazole,voriconazole, itraconazole, erythromycin, or clarithromycin during the study.~* Patients with any type of interstitial lung disease.~For Healthy control Subjects:~* Subjects who are pregnant.~* Subjects with any acute or chronic illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SLE subjects (Type: EXPERIMENTAL): SLE subjects receiving the study drug, Rapamune.

Based on this trial design, predict the completion outcome and termination type (if applicable).